The estimated Net Worth of Kathleen A. Rickard is at least $81.1 Million dollars as of 1 May 2024. Dr Rickard owns over 36,248 units of Verona Pharma Plc stock worth over $79,039,793 and over the last 3 years he sold VRNA stock worth over $1,313,908. In addition, he makes $722,762 as Chief Medical Officer at Verona Pharma Plc.
Dr has made over 11 trades of the Verona Pharma Plc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 36,248 units of VRNA stock worth $71,046 on 1 May 2024.
The largest trade he's ever made was selling 172,520 units of Verona Pharma Plc stock on 8 April 2022 worth over $98,336. On average, Dr trades about 38,343 units every 40 days since 2021. As of 1 May 2024 he still owns at least 2,621,552 units of Verona Pharma Plc stock.
You can see the complete history of Dr Rickard stock trades at the bottom of the page.
Dr. Kathleen A. Rickard is the Chief Medical Officer at Verona Pharma Plc.
As the Chief Medical Officer of Verona Pharma Plc, the total compensation of Dr Rickard at Verona Pharma Plc is $722,762. There are no executives at Verona Pharma Plc getting paid more.
Dr Rickard is 63, he's been the Chief Medical Officer of Verona Pharma Plc since . There are no older and 6 younger executives at Verona Pharma Plc.
Kathleen's mailing address filed with the SEC is 3 MORE LONDON, RIVERSIDE, LONDON, X0, SE1 2RE.
Over the last 4 years, insiders at Verona Pharma Plc have traded over $308,854,297 worth of Verona Pharma Plc stock and bought 5,029,736 units worth $6,770,194 . The most active insiders traders include Andrew Sinclair, Advisors Llc Orbi Med Capit..., and Rishi Gupta. On average, Verona Pharma Plc executives and independent directors trade stock every 18 days with the average trade being worth of $11,234,071. The most recent stock trade was executed by David Zaccardelli on 12 August 2024, trading 400,000 units of VRNA stock currently worth $1,280,000.
verona pharma is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. we are currently focused on developing our novel lead therapeutic candidate in the treatment of chronic obstructive pulmonary fibrosis (copd) and cystic fibrosis (cf), and may expand our pipeline to help address the gaps in treatment of other respiratory diseases. we are led by a team with deep industry experience, including extensive backgrounds in the discovery, development and commercialization of respiratory therapies. in addition, we have established relationships with leading research institutions and advocacy organizations in the respiratory space and have received awards in support of our continued work and innovation. verona pharma is listed on the nasdaq global market in the united states under the ticker symbol vrna and on the london stock exchange in the united kin
Verona Pharma Plc executives and other stock owners filed with the SEC include: